Histogen Inc. Common Stock
HSTO
HSTO was delisted on the 4th of October, 2023.
1 hedge funds and large institutions have $5 invested in Histogen Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 8 closing their positions.
89% less funds holding
Funds holding: 9 → 1 (-8)
100% less capital invested
Capital invested by funds: $9.53K → $5 (-$9.52K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 8
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SF
Synovus Financial
Columbus,
Georgia
|
-$5.17K |
| 2 |
Morgan Stanley
New York
|
-$4.12K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$142 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$46 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$32 |
HSTO Hedge Fund Activity: Q4 2023 in Review
1 of the 6,863 institutional investors tracked by Wall St. Rank reported a position in Histogen Inc. Common Stock (HSTO) for Q4 2023, worth a combined $5 — down 100% from $9.53K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of HSTO and 0 opened new positions — a net loss of 8 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Synovus Financial, exiting entirely with an estimated $5.17K sold.
- 1 institutional investor held Histogen Inc. Common Stock (HSTO) as of Q4 2023, down from 9 in Q3 2023.
- Funds reported $5 of Histogen Inc. Common Stock stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new Histogen Inc. Common Stock positions in Q4 2023 and 8 closed out, a net change of -8 holders.
- The largest Histogen Inc. Common Stock seller in Q4 2023 was Synovus Financial, an estimated $5.17K sold.
Based on aggregated 13F filings for Q4 2023.